Company HBM Holdings Limited

Company HBM Holdings Limited

2142

KYG4403H1002

Pharmaceuticals

Equities

2142

KYG4403H1002

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Delayed Hong Kong S.E. Other stock markets 04:36:01 29/04/2024 BST			5-day change	1st Jan Change
1.29 ^HKD	+3.20%		+19.44%	-33.51%

04-02	HBM Holdings Returns to Profitability in 2023	MT
03-28	HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Companyâs products include batoclimab, mainly used for immune thrombocytopenia (ITP), gravesâ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

Number of employees: 177

HKD in Million	2022	Weight	2023	Weight	Delta
Molecule License Fee 95.6 %	301	94.5 %	670	95.6 %	+122.59%
Research Service Fee 3.5 %	6	2.0 %	25	3.5 %	+287.33%
Technology License Fee 0.9 %	11	3.5 %	6	0.9 %	-45.81%

HKD in Million	2022	Weight	2023	Weight	Delta
United States 87.6 %	55	17.4 %	614	87.6 %	+1,006.92%
China 11.8 %	67	21.0 %	83	11.8 %	+23.83%
Europe 0.3 %	195	61.1 %	2	0.3 %	-98.88%
Others 0.2 %	1	0.4 %	2	0.2 %	+17.34%

Managers	Title	Age	Since
Jing Song Wang CEO	Chief Executive Officer	60	19/07/16
Weihao Xu DFI	Director of Finance/CFO	42	30/11/21
Hong Amy Que CTO	Chief Tech/Sci/R&D Officer	59	31/05/21
Yi Ping Rong CTO	Chief Tech/Sci/R&D Officer	47	-
Li Le Liu CTO	Chief Tech/Sci/R&D Officer	62	30/09/18
Humphrey Gardner CTO	Chief Tech/Sci/R&D Officer	60	13/04/22
Wing Yat Lui SEC	Corporate Secretary	35	-

Members of the board	Title	Age	Since
Albert Collinson BRD	Director/Board Member	66	12/07/23
Robert Kamen BRD	Director/Board Member	79	30/11/16
Wei Wei Chen BRD	Director/Board Member	58	-
Xiao Ping Ye BRD	Director/Board Member	61	30/11/20
Ka Chi Yau BRD	Director/Board Member	66	08/06/21
Jing Song Wang CEO	Chief Executive Officer	60	19/07/16
Yi Ping Rong CTO	Chief Tech/Sci/R&D Officer	47	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	770,240,410	612,108,190 ( 79.47 %)	0	79.47 %

Name	Equities	%	Valuation
Song Wang Jing 7.910 %	60,784,400	7.910 %	11 M $
GIC Special Investments Pte Ltd. 4.992 %	38,363,400	4.992 %	7 M $
Bosera Asset Management Co., Ltd. 0.6232 %	4,789,000	0.6232 %	844 444 $
Dimensional Fund Advisors Ltd. 0.005455 %	41,916	0.005455 %	7 391 $
DFA Australia Ltd. 0.000468 %	3,594	0.000468 %	634 $
Da Cheng Fund Management Co., Ltd. 0.000260 %	2,000	0.000260 %	353 $
Yi Ping Rong 0.000000 %	0	0.000000 %	- $

HBM Holdings Ltd.

Fenglin International Plaza Phase II 420 Fenglin Road

, Shanghai

http://www.harbourbiomed.com

Company calendar

	1st Jan change	Capi.
HBM HOLDINGS LIMITED	-33.51%	117M
CSL LIMITED	-4.65%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals